Bassetti Matteo, Labate Laura, Vena Antonio, Giacobbe Daniele R
Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS.
Department of Health Sciences, University of Genoa, Genoa, Italy.
Curr Opin Infect Dis. 2021 Apr 1;34(2):96-108. doi: 10.1097/QCO.0000000000000714.
To discuss the currently available evidence about the use oritavancin and dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and for other potential indications.
In this review, we briefly summarize the available data on efficacy (from randomized controlled trials) and on effectiveness and cure rates (from observational studies) pertaining to the use of oritavancin and dalbavancin either for ABSSSI or for other indications.
Oritavancin and dalbavancin are valid options for outpatient therapy and early discharge in patients with ABSSSI, especially when adherence to oral therapy cannot be guaranteed or no oral choices are available. Furthermore, it is worth noting that a non-negligible portion (sometimes the majority) of oritavancin and dalbavancin use in available real-life experiences is for indications other than ABSSSI, especially for Gram-positive osteomyelitis and endocarditis. The number of studies on the use of long-acting lipoglycopeptides for these currently off-label indications is rapidly increasing and will help to further optimize the use of these peculiar antibiotics in the forthcoming future.
讨论目前关于奥利万星和达巴万星用于治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）以及其他潜在适应证的现有证据。
在本综述中，我们简要总结了关于奥利万星和达巴万星用于ABSSSI或其他适应证的疗效（来自随机对照试验）以及有效性和治愈率（来自观察性研究）的现有数据。
奥利万星和达巴万星是ABSSSI患者门诊治疗和早期出院的有效选择，尤其是在无法保证口服治疗依从性或没有口服药物选择时。此外，值得注意的是，在现有的实际应用经验中，奥利万星和达巴万星使用的不可忽视的一部分（有时是大部分）是用于ABSSSI以外的适应证，尤其是革兰氏阳性骨髓炎和心内膜炎。关于长效脂糖肽用于这些目前未获批准适应证的研究数量正在迅速增加，并将有助于在未来进一步优化这些特殊抗生素的使用。
